New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen ...
Prolia is administered as a single subcutaneous injection of 60 mg once every six months. Please see the Important Safety Information below. EU Important EU Product Information Calcium and Vitamin D ...
--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...
The Food and Drug Administration (FDA) has approved the use of Prolia (denosumab; Amgen) for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture who are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback